Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Non-Current Debt (2016 - 2017)

Lisata Therapeutics' Non-Current Debt history spans 8 years, with the latest figure at $4.4 million for Q1 2017.

  • For Q1 2017, Non-Current Debt rose 887.37% year-over-year to $4.4 million; the TTM value through Mar 2017 reached $4.4 million, up 887.37%, while the annual FY2016 figure was $2.5 million, 76.68% down from the prior year.
  • Non-Current Debt reached $4.4 million in Q1 2017 per LSTA's latest filing, up from $2.5 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $15.0 million in Q3 2014 to a low of $149667.0 in Q1 2013.
  • Average Non-Current Debt over 5 years is $4.8 million, with a median of $2.9 million recorded in 2014.
  • Peak YoY movement for Non-Current Debt: crashed 99.3% in 2013, then soared 4206.64% in 2014.
  • A 5-year view of Non-Current Debt shows it stood at $348299.0 in 2013, then soared by 137.12% to $825897.0 in 2014, then surged by 1211.13% to $10.8 million in 2015, then crashed by 76.68% to $2.5 million in 2016, then surged by 76.14% to $4.4 million in 2017.
  • Per Business Quant, the three most recent readings for LSTA's Non-Current Debt are $4.4 million (Q1 2017), $2.5 million (Q4 2016), and $4.3 million (Q3 2016).